| CAS |
74011-58-8 |
| Chinese Name |
依诺沙星 |
| English Name |
Enoxacin |
| Synonyms |
AT-2266;CI919;Pd107779;NSC 629661 |
| Molecular Formula |
C15H17FN4O3 |
| Molecular Weight |
320.32 |
| Solubility |
Soluble in DMSO ≥10mg/mL |
| Purity |
HPLC≥98% |
| Appearance |
White to off-white Solid |
| Storage |
Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| EC |
EINECS 1308068-626-2 |
| MDL |
MFCD00133308 |
| SMILES |
O=C(C1=CN(CC)C2=C(C=C(F)C(N3CCNCC3)=N2)C1=O)O |
| InChIKey |
IDYZIJYBMGIQMJ-UHFFFAOYSA-N |
| InChI |
InChI=1S/C15H17FN4O3/c1-2-19-8-10(15(22)23)12(21)9-7-11(16)14(18-13(9)19)20-5-3-17-4-6-20/h7-8,17H,2-6H2,1H3,(H,22,23) |
| PubChem CID |
3229 |
| Target Point |
Bacterial;Topoisomerase |
| Passage |
Anti-infection |
| Background |
Enoxacin interferes with DNA replication and inhibits bacterial DNA spinase and topoisomerase IV. Enoxacin is a specific cancer growth inhibitor. Enoxacin is a miRNA processing activator. |
| Biological Activity |
Enoxacin (AT 2266)， a fluoroquinolone， interferes with DNA replication and inhibits bacterial DNA gyrase (IC50=126 μg/ml) and topoisomerase IV (IC50=26.5 μg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing[1][2][3][4]. |
| IC50 |
Quinolone |
| In Vitro |
Enoxacin (AT 2266) increases siGFP-mediated gene knockdown mediated by siRNA against EGFP in HEK293 cells-based reporter system in a dose-dependent manner， with a median effective concentration (EC50) of ~30 μM， whereas it has no effect on the cells expressing GFP only. Enoxacin (50 μM) promotes the processing of miRNAs and the loading of siRNA duplexes onto RISCs in HEK293 cells[3].Enoxacin has no effect on the processing of pre-let-7 or pre-miR-30a by Dicer alone. However， the addition of Enoxacin can enhance the processing of let-7 or pre-miR-30a by Dicer and TRBP together[3].Enoxacin inhibits 90% Escherichia coli， Klebsiella sp.， Aeromonas sp.， Enterobacter spp.， Serratia spp.， Proteus mirabilis， and Morganella morganii at less than or equal to 0.8 micrograms/ml[5]. |
| In Vivo |
Enoxacin (AT 2266; 100 μM; 2 μl; injected into ear once a day for 3 consecutive days (days 12， 13 and 14)) enhances the the GFP mRNA knockdown efficiency by Lv-siGFP (from 80% to 60%; 40% GFP mRNA level remained)， whereas alone has no effect on GFP expression in GFP transgenic line C57BL/6-Tg(ACTB-EGFP)1Osb/J (10 d old) with lentivirus expressing shGFP (Lv-siGFP; injected into ear for 10 days)[3]. |
| Data Literature Source |
[1]. Sonia Melo，et al.Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci U S A. 2011 Mar 15;108(11):4394-9.
[2]. M Takei，et al. Target preference of 15 quinolones against Staphylococcus aureus，based on antibacterial activities and target inhibition. Antimicrob Agents Chemother. 2001 Dec;45(12):3544-7.
[3]. Ge Shan，et al. A small molecule enhances RNA interference and promotes microRNA processing. Nat Biotechnol. 2008 Aug;26(8):933-40.
[4]. Rengen Fan，et al. Small molecules with big roles in microRNA chemical biology and microRNA-targeted therapeutics. RNA Biol. 2019 Jun;16(6):707-718.
[5]. Chin，N.-X. and H.C. Neu，In vitro activity of enoxacin，a quinolone carboxylic acid，compared with those of norfloxacin，new beta-lactams，aminoglycosides，and trimethoprim. Antimicrobial agents and chemotherapy，1983. 24(5): p. 754-763. |
| Unit |
Bottle |
| Specification |
100mg 10mM*1mL in DMSO 500mg |
English
中文
Manual Download
